Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study by Halcox, Julian P. et al.
RESEARCH ARTICLE Open Access
Prevalence and treatment of atherogenic
dyslipidemia in the primary prevention of
cardiovascular disease in Europe: EURIKA, a
cross-sectional observational study
Julian P. Halcox1*, José R. Banegas2, Carine Roy3, Jean Dallongeville4, Guy De Backer5, Eliseo Guallar6, Joep Perk7,
David Hajage3, Karin M. Henriksson8 and Claudio Borghi9
Abstract
Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this
condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence
and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-
density lipoprotein cholesterol.
Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers,
high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European
Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6%
were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least
50 years with at least one cardiovascular risk factor but no history of cardiovascular disease.
Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein
cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these
markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of
cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia
are not receiving lipid-lowering therapy.
Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary
cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are
not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular
disease is possibly underestimated.
Trial registration: The present study is registered with ClinicalTrials.gov (ID: NCT00882336).
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Background
Although considerable progress has been made in under-
standing and treating associated risk factors, cardiovascu-
lar disease (CVD) remains the leading cause of death
among adults under the age of 75 years in Europe [1].
Traditionally recognized risk factors for CVD include age,
male sex, smoking, lack of exercise, obesity, hypertension,
high levels of low-density lipoprotein cholesterol (LDL-C),
type 2 diabetes mellitus (T2DM), and familial predispos-
ition [2]. In addition, other factors, including atherogenic
dyslipidemia, and elevated lipoprotein(a) or C-reactive
protein (CRP) levels, may also be important considerations
when estimating patients’ overall CVD risk [2–9]. Athero-
genic dyslipidemia has been characterized as a combin-
ation of elevated LDL-C and triglyceride (TG) levels,
decreased high-density lipoprotein cholesterol (HDL-C)
levels, and a preponderance of small-dense LDL-C parti-
cles [10]. Here, we use data from the European Study on
Cardiovascular Risk Prevention and Management in Usual
Daily Practice (EURIKA, ClinicalTrials.gov identifier:
NCT00882336), a cross-sectional observational study
including data on patients from 12 European countries
with at least one traditional CVD risk factor but no history
of cardiovascular events [11, 12], to assess the prevalence
and treatment of two markers of atherogenic dyslipidemia:
elevated TG levels and low HDL-C levels. We have previ-
ously assessed the prevalence of elevated levels of CRP in
the EURIKA population [9]. Among patients without
T2DM not receiving a statin, approximately half had CRP
levels of at least 2 mg/l. The impact of CRP and markers
of atherogenic dyslipidemia on CVD risk is often underes-
timated in clinical practice, with a lack of evidence for the
prevalence and treatment of the latter. TG and CRP levels
are not taken into account in global cardiovascular
risk calculators, such as the Systematic Coronary Risk
Evaluation (SCORE) algorithm [13] and the risk
calculator developed alongside the American College
of Cardiology/American Heart Association (ACC/
AHA) 2013 guidelines [14].
Methods
Study design and participants
EURIKA was a cross-sectional study carried out in 12
European countries (Austria, Belgium, France, Germany,
Greece, Norway, Russia, Spain, Sweden, Switzerland,
Turkey, and the UK) [11]. Included patients were aged
50 years or older and had at least one risk factor for
CVD but no history of cardiovascular events. Data col-
lection started in May 2009 and ended in January 2010,
with a 3-month data-collection period for each country.
The study protocol was approved by the appropriate
clinical research ethics committees in each participating
country, and all patients provided signed informed
consent. The methods for the study have been reported
in detail elsewhere [12]. Briefly, the study sample was
selected in a two-stage process that involved the random
selection of both physicians and patients [12, 15]. In the
first stage, primary care physicians (PCPs) and specialists
involved in CVD prevention (including cardiologists,
endocrinologists, and internal medicine specialists) were
randomly selected for invitation to participate using the
OneKey database (Cegedim Dendrite, Boulogne-Billancourt,
France) [16]. In total, 809 physicians (approximately 60 per
country) agreed to participate in EURIKA, 64% of whom
were PCPs [15]. In the second stage, participating physicians
sequentially invited patients who met the selection criteria
(aged ≥50 years, who were free from CVD but with at least
one major cardiovascular risk factor [dyslipidemia, hyperten-
sion, current smoker, T2DM, or obesity]). Hypertension was
defined as having a systolic blood pressure (SBP) of at least
140 mmHg, a diastolic blood pressure (DBP) of at least
90 mmHg, or receiving treatment with antihypertensive
medications. Approximately 600 patients were included per
country, with a final sample size of 7641.
Assessment of CVD risk factors
Demographic information and other details of participat-
ing patients were gathered from medical records and pa-
tient interviews. For each patient, a physical examination
was conducted, blood pressure measured, and a 12-h
fasting blood sample collected within 1 day of the initial
outpatient consultation [12]. Blood pressure was mea-
sured under standardized conditions, and blood sample
analysis was performed at a central laboratory (BioAna-
lytical Research Corporation, Ghent, Belgium), with the
exception of patients in Russia (approximately 5% of the
total patient population), for whom a laboratory analysis
was performed locally. HDL-C concentration was
measured using a modified enzymatic method, total
cholesterol concentration using the cholesterol oxi-
dase/p-aminophenazone (CHOD-PAP) method, TG
concentration using the glycerol-3-phosphate-oxidase/
p-aminophenazone (GPO-PAP) method, and CRP
levels using a high-sensitivity immunoturbidimetric
method (all using the Roche Modular P chemistry
analyzer [Roche Diagnostics, Indianapolis, IN, USA]).
LDL-C concentration was calculated by the Friede-
wald formula [17]. The ACC/AHA risk calculator was
used to calculate 10-year CVD risk scores, and the
version of the SCORE algorithm updated to consider
patients’ total cholesterol and HDL-C levels as
independent variables (SCORE-HDL) [6, 13, 14, 18].
Patients were considered to be at high CVD risk if
they had a score of at least 7.5% when using the
ACC/AHA risk calculator, or at least 5% when using
the SCORE-HDL algorithm.
High TG levels were defined as those of at least
2.3 mmol/l (200 mg/dl), and low HDL-C levels as those
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lower than 1.0 mmol/l (40 mg/dl) in men and lower than
1.3 mmol/l (50 mg/dl) in women. For statin treatment,
therapy was categorized as low or moderate intensity
(pravastatin 5–40 mg/day, simvastatin 2.5–80 mg/day,
lovastatin 10–80 mg/day, fluvastatin 10–80 mg/day,
atorvastatin 5–40 mg/day, or rosuvastatin 5–20 mg/day),
or high intensity (atorvastatin ≥40 mg/day or rosuvasta-
tin ≥20 mg/day).
Statistical analyses
Data are presented as mean and standard deviation for
continuous variables, and as frequency and percentage
for categorical variables. Comparisons between groups
were performed using Student’s t-tests for normally dis-
tributed continuous variables, Mann–Whitney U tests
for continuous variables that were not normally distrib-
uted, and χ2 or Fisher’s exact tests for categorical vari-
ables, as appropriate. A p value below 0.05 was
considered significant. Multivariate logistic regression
was performed to assess factors associated with high TG
and/ or low HDL-C levels. Variables considered in the
multivariate analysis included country of origin, age, sex,
hypertension, obesity, T2DM status, smoking status,
total cholesterol levels, CRP levels, use of β-blockers,
use of α-adrenergic antagonists, and use of diuretics. A
stepwise (bidirectional) selection method was used to
keep only those variables statistically significantly associ-
ated at the p < 0.05 level in the final model. Statistical
analyses were performed using SAS version 9.2 (SAS In-
stitute Inc., Cary, NC, USA).
Results
Overall patient characteristics
The EURIKA study population consisted of 7641 pa-
tients with a mean age of 63.2 years, of whom 48.4%
were men and of whom 95.6% were White/Caucasian
(Table 1). Mean body mass index (BMI) was 28.9 kg/m2,
21.0% of patients were current smokers, and 26.8% of
participants had T2DM. Mean alcohol consumption of
the EURIKA study population was 5.7 units/week, and
19.8% of patients reported undertaking no physical exer-
cise. Almost three-quarters (72.8%) of patients had
hypertension.
Prevalence of high TG and/or low HDL-C levels
Among the overall population that included treated and
untreated patients, a total of 1591 patients (20.8%) were
classified as having high TG levels (≥ 2.3 mmol/l), 1691
(22.1%) had low HDL-C levels (men: < 1.0 mmol/l;
women: < 1.3 mmol/l), and 759 (9.9%) had both high TG
and low HDL-C levels (Table 1; Fig. 1). A very small pro-
portion of patients in the overall population had very
high TG levels (> 5 mmol/L [1.9%]; > 10 mmol/L
[0.3%]). Similarly, only 0.1% of the EURIKA population
had very low HDL-C levels (< 0.5 mmol/L). The mean
ages of patients in the subpopulations with high TG
levels, low HDL-C levels, or both were similar to that of
the overall population, as were mean SBP, DBP, and the
proportions of patients with hypertension. There were
higher proportions of patients classified as obese
(BMI ≥ 30 kg/m2) in the subpopulations with high TG
levels, low HDL-C levels, or both than in the overall
population. There was a higher proportion of men with
high TG levels than women in the patient population;
conversely, the proportion of women was higher among
patients with low HDL-C levels when compared with
men. The proportion of patients who had T2DM was
higher among patients with markers of atherogenic dys-
lipidemia than in the overall population. There were pa-
tients within the EURIKA population, both male and
female, exceeding the recommended weekly limit of al-
cohol consumption. There were similar proportions of
patients undertaking no physical exercise in the subpop-
ulations with high TG levels, low HDL-C levels, or both
to those in the overall population. We observed cross-
country variation in the proportions of patients with
markers of atherogenic dyslipidemia (Additional file 1:
Table S1).
Treatment of high TG and/or low HDL-C levels
With regard to treatment, over half of patients in the
overall population and in the subpopulations with
markers of atherogenic dyslipidemia were not receiving
any form of lipid-lowering therapy (LLT, Table 1). Of pa-
tients receiving LLT, most were receiving a statin alone.
Only small proportions of patients were receiving ezeti-
mibe, a fibrate, or nicotinic acid. Of those patients receiving
a statin, most were receiving a low- or moderate-intensity
statin; only a small proportion of patients (≤ 5%) were
receiving a high-intensity statin (Fig. 2).
Differences in the prevalence of high TG and/or low HDL-
C levels according to statin treatment, T2DM, and CVD
risk status
Patients in the overall population were described accord-
ing to whether or not they were receiving statin therapy,
and then further stratified according to the presence or
absence of T2DM, and then, among patients without
T2DM, overall CVD risk assessed using either the ACC/
AHA or SCORE-HDL risk calculators [6, 14]. Higher
proportions of patients with T2DM were found to have
high TG and/or low HDL-C levels than patients without
T2DM (Fig. 3). Among patients without T2DM, greater
proportions of patients in the higher overall CVD risk
categories had high TG and/or low HDL-C levels than
patients in lower overall CVD risk categories. These
trends were observed in both statin-treated and non-
statin-treated patients. Given that the SCORE-HDL and
Halcox et al. BMC Cardiovascular Disorders  (2017) 17:160 Page 3 of 11
Table 1 Patient characteristics and treatment
Overall
(N = 7641)
High TG
(n = 1591)
Low HDL-C
(n = 1691)
High TG and
low HDL-C
(n = 759)
Age (year) 63.2 (9.0) 61.5 (8.4) 62.0 (8.8) 60.8 (8.5)
Sex
Male (n, %) 3696 (48.4) 903 (56.8) 623 (36.8) 330 (43.5)
Female (n, %) 3945 (51.6) 688 (43.2) 1068 (63.2) 429 (56.5)
Race
White/Caucasian (n, %) 6675 (95.6) 1408 (94.9) 1515 (94.3) 681 (94.7)
Middle East/North African (n, %) 74 (1.1) 15 (1.01) 23 (1.4) 9 (1.3)
South Asian (n, %) 63 (0.9) 16 (1.01) 21 (1.3) 6 (0.8)
Other Asian countries (n, %) 34 (0.5) 10 (0.7) 8 (0.5) 2 (0.3)
South American origin (n, %) 22 (0.3) 6 (0.4) 8 (0.5) 4 (0.6)
Sub-Saharan (n, %) 15 (0.2) 1 (0.1) 2 (0.1) 1 (0.1)
Caribbean (n, %) 14 (0.2) 2 (0.1) 2 (0.1) 1 (0.1)
Other (n, %) 82 (1.2) 26 (1.8) 28 (1.7) 15 (2.1)
Current smoker (n, %) 1608 (21.0) 393 (24.7) 397 (23.5) 201 (26.5)
BMI (kg/m2) 28.9 (5.5) 30.6 (5.4) 30.9 (5.8) 31.3 (5.4)
≥ 30 kg/m2 (n, %) 2788 (37.0) 783 (49.6) 858 (50.7) 410 (54.0)
T2DMa (n, %) 2046 (26.8) 562 (35.3) 617 (36.5) 305 (40.2)
Blood pressure
Hypertensionb (n, %) 5559 (72.8) 1193 (75.2) 1278 (75.6) 564 (74.3)
SBP (mmHg) 135.1 (16.6) 136.9 (16.7) 135.5 (17.1) 136.0 (17.0)
DBP (mmHg) 80.9 (9.9) 82.3 (10.1) 81.7 (10.0) 82.5 (9.9)
Serum lipid levels
TC (mmol/l) 5.5 (1.1) 5.9 (1.2) 5.2 (1.2) 5.7 (1.2)
LDL-C (mmol/l) 3.2 (1.0) 3.3 (1.1) 3.1 (1.0) 3.2 (1.0)
Non-HDL-C (mmol/l) 4.0 (1.1) 4.7 (1.2) 4.2 (1.2) 4.7 (1.2)
TG (mmol/l) 1.8 (1.3) 3.4 (1.9) 2.6 (2.0) 3.8 (2.5)
HDL-C (mmol/l) 1.4 (0.4) 1.2 (0.3) 1.0 (0.2) 1.0 (0.2)
CRP (mg/l) 4.2 (8.7) 4.4 (6.3) 6.0 (12.2) 5.0 (7.5)
LLT
At least one LLT (n, %) 3278 (42.9) 757 (47.6) 749 (44.3) 349 (46.0)
Statin alone (n, %) 2862 (37.5) 598 (37.6) 617 (36.5) 258 (34.0)
Statin + other LLT (n, %) 178 (2.3) 74 (4.7) 57 (3.4) 43 (5.7)
Other LLT alone (n, %) 238 (3.1) 85 (5.3) 75 (4.4) 48 (6.3)
Ezetimibe (n, %) 151 (2.0) 57 (3.6) 45 (2.7) 35 (4.6)
Fibrate (n, %) 220 (2.9) 84 (5.3) 68 (4.0) 45 (5.9)
Nicotinic acid (n, %) 6 (0.1) 3 (0.2) 4 (0.2) 3 (0.4)
Alcohol consumptionc
(units/week) 5.7 (11.3) 6.4 (12.2) 3.2 (6.4) 3.6 (6.8)
> 14 units/week
(male; n, %)
529 (17.8) 129 (18.0) 47 (9.6) 27 (10.3)
> 7 units/week
(female; n, %)
272 (8.9) 49 (9.4) 43 (5.5) 22 (6.9)
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ACC/AHA risk calculators are valid only for assessing
risk in routine clinical practice in patients up to 65 and
79 years of age, respectively, we went further in our
analysis and stratified according to these age limits
(Additional file 2: Figure S1 and Additional file 3: Figure
S2). For the subgroups of patients up to the age of
65 years (SCORE-HDL) and 79 years (ACC/AHA), the
proportions of patients with high TG and/or low HDL-C
levels were similar to or slightly larger than the corre-
sponding CVD risk groups for the whole population.
Factors associated with high TG and/or low HDL-C levels
Factors significantly associated with high TG levels, low
HDL-C levels, or both were assessed using multivariate
analysis (p < 0.0001; Fig. 4). Female sex was positively as-
sociated with low HDL-C status but negatively associated
with high TG levels. Other cardiovascular risk factors, in-
cluding T2DM, obesity, smoking, and hypertension (indi-
cated by the use of β-blockers) were positively associated
with markers of atherogenic dyslipidemia. The association
of markers of atherogenic dyslipidemia with CRP levels
was found to be significant only after adjusting for con-
founding factors among patients with low HDL-C levels.
Some variation in patients’ likelihood of having markers of
atherogenic dyslipidemia was seen between countries of
origin, when assessed relative to the UK.
Association between high TG and/or low HDL-C levels
and CRP
In the overall population, mean CRP was 4.2 mg/l, and
this was increased in patients with high TG levels
(4.4 mg/l), low HDL-C levels (6.0 mg/l), and both
(5.0 mg/l) (Table 1). Patients in the overall population
with high TG levels and/or low HDL-C levels were cate-
gorized by plasma CRP concentrations into two subpop-
ulations: CRP lower than 1 mg/l, 1–< 3 mg/l, or at least
3 mg/l; and CRP lower than 2 mg/l or at least 2 mg/l.
Greater proportions of patients had CRP levels of either
Table 1 Patient characteristics and treatment (Continued)
Physical exercise
No exercise (n, %) 1489 (19.8) 368 (23.5) 406 (24.3) 191 (25.5)
Only light physical activity per week (n, %) 3782 (50.2) 807 (51.5) 910 (54.6) 403 (53.8)
Heavy physical activity 1–2 times per week (n, %) 1232 (16.4) 220 (14.1) 203 (12.2) 90 (12.0)
Heavy physical activity ≥3 times per week (n, %) 1026 (13.6) 171 (10.9) 149 (8.9) 65 (8.7)
Data are mean (standard deviation) unless otherwise indicated
High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and <1.3 mmol/l in women
aConsidered present if the diagnosis was documented in the medical records
bSBP ≥ 140 mmHg, DBP ≥ 90 mmHg, or receiving antihypertensive medication
cModerate alcohol consumption of 14 units/week (male) and 7 units/week (female) is outlined in the 2016 ESC/EAS guidelines for management of
dyslipidemias [3]
Abbreviations: BMI body mass index, CRP C-reactive protein, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein
cholesterol, LLT lipid-lowering therapy, SBP systolic blood pressure, T2DM type 2 diabetes mellitus, TC total cholesterol, TG triglyceride
Fig. 1 Prevalence of high TG and/or low HDL-C levels in the EURIKA population. Percentages indicated are of the total EURIKA population
(N = 7641). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women Abbreviations: EURIKA European Study on
Cardiovascular Risk Prevention and Management in Usual Daily Practice, HDL-C high-density lipoprotein cholesterol, TG triglyceride
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at least 2 mg/l or at least 3 mg/l among those with high
TG levels and/or low HDL-C levels than in the overall
population, with between approximately 60 and 70% of
patients with markers of atherogenic dyslipidemia having
CRP levels of at least 2 mg/l, and between 45 and 50%
having CRP levels of at least 3 mg/l (Fig. 5).
Discussion
We have analyzed the number of patients with high
levels of TG and/or low levels of HDL-C, two markers
of atherogenic dyslipidemia, in the large clinical EUR-
IKA population. We have shown that 20.8% of patients
had high TG levels, 22.1% had low HDL-C levels, and
9.9% had both high TG and low HDL-C levels. Very few
patients in our cohort had very high TG levels or very
low HDL-C levels; it is likely that other comorbidities or
underlying genetic factors may affect these individuals.
Our analysis also reveals that the proportion of patients
with T2DM (who are already considered to be at high
risk of CVD) with high TG and/or low HDL-C levels is
higher than that of patients without T2DM. In addition,
when categorizing patients without T2DM according to
the ACC/AHA or SCORE-HDL risk calculators, larger
proportions of patients with high TG and/or low HDL-C
levels are in the higher risk categories than in the lower
risk categories. Cross-country variation in the propor-
tions of patients with high TG and/or low HDL-C levels
was observed and could be a consequence of genetic,
cultural or socio-economic factors that have been dis-
cussed elsewhere [11]. We are unable to provide defini-
tive explanations in the analysis presented here. Our
multivariate analysis revealed that female sex was posi-
tively associated with low HDL-C status, which may
reflect the specific selection criteria for the EURIKA
population as females have higher HDL-C levels than
males in the general population. Thus, our data suggest
that European women with at least one cardiovascular
risk factor but no history of cardiovascular disease are
actually more likely than men to have a low HDL-C
status.
The EURIKA study has provided important insights
into the effectiveness of current practices related to pri-
mary CVD prevention in Europe [9, 11, 19]. The pri-
mary analysis of the EURIKA data demonstrated that a
substantial proportion of patients had CVD risk factors
that remained uncontrolled, despite receiving treatment
[11]. A follow-up analysis of CRP levels in the EURIKA
population revealed that among patients without T2DM
who were not receiving statin treatment, more than one-
third had CRP levels of at least 3 mg/l, while almost half
had CRP levels of at least 2 mg/l [9]. Here, our analysis
of CRP levels demonstrates that a greater proportion of
patients with high TG and/or low HDL-C levels also
have low-grade inflammation, evident by elevated CRP
levels, than in the overall at-risk population. These pa-
tients are likely to be at an even higher risk of CVD than
those with either atherogenic dyslipidemia or elevated
CRP levels alone.
We have previously reported on the proportions of pa-
tients in EURIKA who were not receiving any form of
LLT and who had uncontrolled LDL-C levels [19]. Ele-
vated LDL-C levels are among the primary causal risk
factors for cardiovascular disease, and are a component
of the atherogenic dyslipidemia profile [2]. Over one-
third of patients defined as being at high risk of CVD in
our previous analysis were not receiving any form of
Fig. 2 Proportion of patients treated with or without statins according to markers of atherogenic dyslipidemia. Data were missing for 26 patients
in the overall population, 8 patients in the high TG group, 5 patients in the low HDL-C group, and 2 patients in the high TG and low HDL-C
group. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. Abbreviations: HDL-C
high-density lipoprotein cholesterol, TG triglyceride
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LLT [19]. Moreover, LDL-C levels were controlled in
only 40% of these patients at high risk of CVD who were
receiving LLT [19]. Findings from the Centralized Pan-
Regional Surveys on the Undertreatment of Hyperchol-
esterolemia (CEPHEUS) were similar; only 49.4% of pa-
tients achieved their recommended LDL-C levels [20]. A
literature review from 2004 also reported a widespread
failure in the attainment of recommended lipid levels in
patients treated with LLT [21]. Similarly, in the current
analysis, we observed that approximately 55% of patients
with high TG levels, low HDL-C levels, or both were not
taking any form of LLT. Furthermore, of those patients
treated with statins, the majority were using low-
intensity statins. These observations build on our previ-
ous arguments that there is a clear opportunity to im-
prove rates of treatment for primary CVD prevention,
and for patients with dyslipidemia in particular.
Whether or not TG levels are a causal risk factor for
CVD is debated [22, 23]; patients with high TG levels
often have additional CVD risk factors; TG levels in hu-
man plasma are highly variable and are strongly associ-
ated with low HDL-C levels, which makes it difficult to
separate the contributions of these two components
[22–25]. Nevertheless, several population studies and
meta-analyses have shown a significant link between TG
levels and CVD risk, independent of other CVD risk
Fig. 3 Proportion of patients with markers of atherogenic dyslipidemia, according to T2DM status and CVD risk. (a) Non-statin - treated patients;
(b) statin-treated patients. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women.
aACC/AHA risk calculator [14]. bSCORE-HDL risk calculator [6, 18]. Abbreviations: ACC American College of Cardiology, AHA American Heart Associ-
ation, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipopro-
tein, T2DM type 2 diabetes mellitus, TG triglyceride
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factors, including HDL-C levels [26–28]. A topic of de-
bate has been whether measuring non-fasting TG levels
is a better predictor of CVD than measuring fasting TG
levels, with some studies showing a stronger association
between non-fasting TG levels and CVD risk than fast-
ing TG levels [24, 29]. European guidelines have previ-
ously recommended the measurement of fasting TG
levels, as was done in EURIKA, owing to a lack of
standardization of non-fasting TG measurements [30].
Guidelines recommend lifestyle interventions in patients
with moderately elevated TG levels (e.g. reduction in al-
cohol consumption, dietary modifications, or increased
aerobic exercise) [23]. A reduction in alcohol
consumption is of particular importance, as patients
with elevated TG levels are likely to experience further
increases from consuming even small quantities of alco-
hol [3]. Our analysis reveals that within the EURIKA
population, small proportions of patients with elevated
TG levels are consuming more units of alcohol than the
recommended weekly limit. Furthermore, almost 20% of
the overall population reported undertaking no physical
exercise. In patients with TG levels above 500 mg/dl,
pharmacological intervention in the form of fibrates, ni-
acins, or omega-3 fish oils should be considered [23].
The EURIKA study has the strength of allowing
analysis of data from a large sample of patients from
Fig. 4 Multivariate analysis of factors associated with markers of atherogenic dyslipidemia. (a) Low HDL-C levels; (b) high TG levels; (c) low HDL-C
and high TG levels. p < 0.0001 for all factors. Countries of origin with an OR that was not significant have been omitted. aPer year. bRelative to
male participants. cRelative to not having T2DM. dBMI ≥ 30 kg/m2, relative to not being obese. ePer mmol/l. fPer mg/l. gRelative to never smoking.
hRelative to non-use. iRelative to the UK. Abbreviations: BMI body mass index, CI confidence interval, CRP C-reactive protein, HDL-C high-density
lipoprotein cholesterol, OR odds ratio, T2DM type 2 diabetes mellitus, TG triglyceride
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multiple European countries according to standardized
procedures. Almost all blood samples were analyzed at
the same location, with the exception of patients from
Russia. A limitation of the study, however, is that it is
cross-sectional, and therefore does not allow conclusions
to be drawn regarding the longitudinal association of
individual factors with CVD risk. The EURIKA study
recruited individuals over 50 years of age with at least
one major CVD risk factor, including dyslipidemia.
Therefore, the proportion of patients identified with low
HDL-C and high TG levels is likely to be greater than in
people of the same age in the general population. Previ-
ous cohort studies investigating the predictive power of
HDL-C levels in CVD risk have measured HDL-C using
precipitation methods. In EURIKA, HDL-C levels were
measured using an enzymatic method; it has been
demonstrated that enzymatic methods result in higher
recorded HDL-C levels than precipitation methods [31].
Therefore, it is possible that we have underestimated the
proportion of the cohort with low HDL-C levels. The
participation rate among invited physicians was also low;
however, potential patient selection bias is likely to have
Fig. 5 Association between markers of atherogenic dyslipidemia and CRP. (a) CRP levels of < 1 mg/L, 1–< 3 mg/L or ≥ 3 mg/L; (b) CRP levels <
2 mg/L or ≥ 2 mg/L. Data were missing for 76 patients in the overall population, and for 1 patient in each of the dyslipidemia groups. Data
within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. Abbreviations: CRP C-reactive protein,
HDL-C high-density lipoprotein cholesterol, TG triglyceride
Halcox et al. BMC Cardiovascular Disorders  (2017) 17:160 Page 9 of 11
been reduced by the high participation rate among
invited patients, and the randomized method of patient
selection. Finally, we did not calculate the ratio of TG to
HDL-C concentrations in the EURIKA study; however,
this marker has been proposed to correlate with insulin
resistance and thus could be used to identify patients at
risk of CVD [32].
Conclusions
A considerable proportion of primary prevention pa-
tients at risk of CVD in routine clinical practice have
high levels of TG and low levels of HDL-C. Many of
these patients also have evidence of elevated CRP levels,
reflecting low-grade inflammation. Therefore, these pa-
tients’ absolute CVD risk may be underestimated by
current European and US global risk calculators. These
patients may benefit from more intensive or better-
tailored treatment options to address their overall CVD
risk, in accordance with evidence-based guidelines.
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